ACOG
Close Search
Menu

Increasing Health Equity in Gynecologic Cancer Screening, Early Diagnosis, and Treatment

A MicroRound presented by Shirley Mei, MD, FACOG

References

  1. American Cancer Society. Cancer facts and figures 2024. ACS; 2024. Accessed July 22, 2024. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html
  2. Bian SX, Chen DH, Lin E. Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database. Cancer Med 2021;10:575-85. doi: 10.1002/cam4.3625
  3. Bregar AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, Schorge JO, Rice LW, et al. Disparities in receipt of care for high-grade endometrial cancer: a National Cancer Data Base analysis. Gynecol Oncol 2017;145:114-21. doi: 10.1016/j.ygyno.2017.01.024
  4. Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol 2014;134:60-7. doi: 10.1016/j.ygyno.2014.03.561
  5. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol 2011;122:319-23. doi: 10.1016/j.ygyno.2011.04.047
  6. Centers for Disease Control and Prevention. Glossary of terms. CDC; 2023. Accessed August 2, 2024. https://www.cdc.gov/dhdsp/health_equity/glossary.htm#
    Chase DM, Lin CC, Craig CD, Fedewa SA, Virgo KS, Farley JH, et al. Disparities in vulvar cancer reported by the National Cancer Database: influence of sociodemographic factors. Obstet Gynecol 2015;126:792-802. doi: 10.1097/AOG.0000000000001033
  7. Chen T, Kharazmi E, Fallah M. Race and ethnicity-adjusted age recommendation for initiating breast cancer screening. JAMA Netw Open 2023;6:e238893. doi: 10.1001/jamanetworkopen.2023.8893
  8. Cook LS, Nelson HE, Cockburn M, Olson SH, Muller CY, Wiggins CL. Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites. Cancer Causes Control 2013;24:61-9. doi: 10.1007/s10552-012-0090-z
  9. Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting Black women. Cancer Epidemiol Biomarkers Prev 2015;24:1407-15. doi: 10.1158/1055-9965.EPI-15-0316
  10. Cragun D, Weidner A, Kechik J, Pal T. Genetic testing across young Hispanic and non-Hispanic White breast cancer survivors: facilitators, barriers, and awareness of the Genetic Information Nondiscrimination Act. Genet Test Mol Biomarkers 2019;23:75-83. doi: 10.1089/gtmb.2018.0253
  11. Doll KM, Winn AN, Goff BA. Untangling the Black-White mortality gap in endometrial cancer: a cohort simulation. Am J Obstet Gynecol 2017;216:324-5. doi: 10.1016/j.ajog.2016.12.023
  12. Donkers H, Bekkers R, Massuger L, Galaal K. Systematic review on socioeconomic deprivation and survival in endometrial cancer. Cancer Causes Control 2019;30:1013-22. doi: 10.1007/s10552-019-01202-1
  13. Fader AN, Habermann EB, Hanson KT, Lin JF, Grendys EC, Dowdy SC. Disparities in treatment and survival for women with endometrial cancer: a contemporary national cancer database registry analysis. Gynecol Oncol 2016;143:98-104. doi: 10.1016/j.ygyno.2016.07.107
  14. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer 2009;115:4210-7. doi: 10.1002/cncr.24482
  15. Fedewa SA, Lerro C, Chase D, Ward EM. Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database. Gynecol Oncol 2011;122:63-8. doi: 10.1016/j.ygyno.2011.03.010
  16. Franzoi MA, Schwartsmann G, de Azevedo SJ, Geib G, Zaffaroni F, Liedke PE. Differences in breast cancer stage at diagnosis by ethnicity, insurance status, and family income in young women in the USA. J Racial Ethn Health Disparities 2019;6:909-16. doi: 10.1007/s40615-019-00591-y
  17. Ganguly AP, Baker KK, Redman MW, McClintock AH, Yung RL. Racial disparities in the screening mammography continuum within a heterogeneous health care system. Cancer 2023;129:3171-81. doi: 10.1002/cncr.34632
  18. Geltzeiler CB, Tsikitis VL, Kim JS, Thomas CR Jr, Herzig DO, Lu KC. Variation in the use of chemoradiotherapy for stage II and III anal cancer: analysis of the National Cancer Data Base. Ann Surg Oncol 2016;23:3934-40. doi: 10.1245/s10434-016-5431-9
  19. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin 2022;72:524-41. doi: 10.3322/caac.21754
  20. Henley SJ, Miller JW, Dowling NF, Benard VB, Richardson LC. Uterine cancer incidence and mortality - United States, 1999-2016. MMWR Morb Mortal Wkly Rep 2018;67:1333-8. doi: 10.15585/mmwr.mm6748a1
  21. Hicks ML, Phillips JL, Parham G, Andrews N, Jones WB, Shingleton HM, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer 1998;83:2629-37. doi: 10.1002/(SICI)1097-0142(19981215)83:12
  22. Huffman DL, Jayakrishnan TT, Vannatter BL, Monga DK, Finley GG, McCormick JT, et al. Chemotherapy use in early stage anal canal squamous cell carcinoma and its impact on long-term overall survival. Cancer Treat Res Commun 2021;27:100347. doi: 10.1016/j.ctarc.2021.100347
  23. Jones T, Trivedi MS, Jiang X, Silverman T, Underhill M, Chung WK, et al. Racial and ethnic differences in BRCA1/2 and multigene panel testing among young breast cancer patients. J Cancer Educ 2021;36:463-9. doi: 10.1007/s13187-019-01646-8
  24. Karanth S, Fowler ME, Mao X, Wilson LE, Huang B, Pisu M, et al. Race, socioeconomic status, and health-care access disparities in ovarian cancer treatment and mortality: systematic review and meta-analysis. JNCI Cancer Spectr 2019;3:pkz084. doi: 10.1093/jncics/pkz084
  25. Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. J Clin Oncol 2021;39:1631-40. doi: 10.1200/JCO.20.02785
  26. Le Blanc JM, Heller DR, Friedrich A, Lannin DR, Park TS. Association of Medicaid expansion under the Affordable Care Act with breast cancer stage at diagnosis. JAMA Surg 2020;155:752-8. doi: 10.1001/jamasurg.2020.1495
  27. Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, et al. Achieving universal genetic assessment for women with ovarian cancer: are we there yet? A systematic review and meta-analysis. Gynecol Oncol 2021;162:506-16. doi: 10.1016/j.ygyno.2021.05.011
  28. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol Oncol 2013;130:652-9. doi: 10.1016/j.ygyno.2013.05.020
  29. Mahdi H, Kumar S, Hanna RK, Munkarah AR, Lockhart D, Morris RT, et al. Disparities in treatment and survival between African American and White women with vaginal cancer. Gynecol Oncol 2011;122:38-41. doi: 10.1016/j.ygyno.2011.03.018
  30. Malagon-Blackwell EM, Seagle BL, Nieves-Neira W, Shahabi S. The Hispanic paradox in endometrial cancer: a National Cancer Database study. Gynecol Oncol 2017;146:351-8. doi: 10.1016/j.ygyno.2017.05.026
  31. Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen L. Disparities in genetics assessment for women with ovarian cancer: can we do better? Gynecol Oncol 2018;149:84-8. doi: 10.1016/j.ygyno.2017.10.034
  32. Markossian TW, Hines RB, Bayakly R. Geographic and racial disparities in breast cancer-related outcomes in Georgia. Health Serv Res 2014;49:481-501. doi: 10.1111/1475-6773.12096
  33. Pace LE, Ayanian JZ, Wolf RE, Knowlton R, Gershman ST, Hawkins SS, et al. BRCA1/2 testing among young women with breast cancer in Massachusetts, 2010-2013: an observational study using state cancer registry and all-payer claims data. Cancer Med 2022;11:2679-86. doi: 10.1002/cam4.4648
  34. Patel KS, Alhatem A, Gadde U, Ahlawat S, Lambert C, Schwartz RA, et al. Insurance status and level of education predict disparities in receipt of treatment and survival for anal squamous cell carcinoma. Cancer Epidemiol 2020;67:101723. doi: 10.1016/j.canep.2020.101723
  35. Randall TC, Armstrong K. Differences in treatment and outcome between African-American and white women with endometrial cancer. J Clin Oncol 2003;21:4200-6. doi: 10.1200/JCO.2003.01.218
  36. Rauh-Hain JA, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, et al. Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time. Am J Obstet Gynecol 2013;209:468.e1-10. doi: 10.1016/j.ajog.2013.07.021
  37. Reid S, Cragun D, Tezak A, Weidner A, Moore J, Mayer IA, et al. Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. Genet Med 2020;22:1088-93. doi: 10.1038/s41436-020-0762-0
  38. Ren J, Gong Y, Ling H, Hu X, Shao Z. Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Res Treat 2019;173:225-37. doi: 10.1007/s10549-018-4956-y
  39. Rodriguez AM, Schmeler KM, Kuo Y. Disparities in endometrial cancer outcomes between non-Hispanic White and Hispanic women. Gynecol Oncol 2014;135:525-33. doi: 10.1016/j.ygyno.2014.10.021
  40. Scalici J, Finan MA, Black J, Harmon MD, Nicolson W, Lankes HA, et al. Minority participation in Gynecologic Oncology Group (GOG) studies. Gynecol Oncol 2015;138:441-4. doi: 10.1016/j.ygyno.2015.05.014
  41. Shah CA, Goff BA, Lowe K, Peters WA III, Li CI. Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol 2009;113:1038-45. doi: 10.1097/AOG.0b013e31819fe844
  42. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 2003;98:176-86. doi: 10.1002/cncr.11484
  43. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [published erratum appears in CA Cancer J Clin 2024;74:203]. CA Cancer J Clin 2024;74:12-49. doi: 10.3322/caac.21820
  44. Stenzel AE, Schlecht NF, Moysich KB. Racial/ethnic disparities in survival among women diagnosed with invasive cancer of the anal canal: an analysis of Surveillance, Epidemiology, and End Results (SEER) data. J Gastrointest Cancer 2021;52:854-62. doi: 10.1007/s12029-020-00472-2
  45. Sud S, Holmes J, Eblan M, Chen R, Jones E. Clinical characteristics associated with racial disparities in endometrial cancer outcomes: a Surveillance, Epidemiology and End Results analysis. Gynecol Oncol 2018;148:349-56. doi: 10.1016/j.ygyno.2017.12.021
  46. Tait SD, Ren Y, Horton CC, Oshima SM, Thomas SM, Wright S, et al. Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: a retrospective review of 90,000 women. Cancer 2021;127:2515-24. doi: 10.1002/cncr.33473
  47. Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, et al. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat 2023;200:75-83. doi: 10.1007/s10549-023-06943-x
  48. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol 2008;111:173-8. doi: 10.1016/j.ygyno.2008.08.013
  49. U.S. Preventive Services Task Force. Final recommendation statement: breast cancer screening. USPSTF; 2024. Accessed July 22, 2024. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening

MicroRounds

MicroRounds are short educational video presentations that tackle important clinical topics and highlight research gaps in early-onset breast and gynecologic cancers.

View All MicroRounds